A carregar...
Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
Burosumab (Crysvita(®)), a fully human IgG1 monoclonal antibody directed at fibroblast growth factor 23 (FGF23), is indicated for the treatment of X-linked hypophosphatemia (XLH), a condition associated with excessive FGF23 production. It directly addresses the excessive FGF23 activity in patients w...
Na minha lista:
| Publicado no: | Drugs Ther Perspect |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6223702/ https://ncbi.nlm.nih.gov/pubmed/30459508 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40267-018-0560-9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|